podcast
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Healthcare
IRLAB Therapeutics has received a US$2.5m milestone payment from the McQuade Center for Strategic Research and Development for dosing the first patient in a new Phase I trial with IRL757. This is the second clinical study for the candidate (the first is supported by The Michael J. Fox Foundation), and is focused on assessing the pharmacokinetics, safety and tolerability of single ascending oral doses of IRL757 in healthy individuals aged 65 and older. It is expected to conclude in late-Q424.
Healthcare | Comment
Industrials | Comment
Consumer | Comment
Healthcare | Comment
Consumer | Comment
Get access to the very latest content matched to your personal investment style.